Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma.
Two patients with persistent disease after allografting for multiple myeloma received donor T-cell lymphocyte infusion (DLI) (1.5 x 10(8) and 7 x 10(7)) to induce a graft-vs.-myeloma effect for further tumour regression after withdrawal of immunosuppression. The interval between stem cell transplantation and DLI was 8 and 14 months respectively. Both patients converted from partial to complete remission, lasting 12+ and 28+ months. Immunofixation became negative after 3 and 4 months. The main toxicity was grade II and III acute graft-vs.-host disease (GvHD) and limited or extensive chronic GvHD in each patient. We conclude that DLI induced further tumour reduction in patients with persistent disease after allografting for multiple myeloma.
Kröger
N
N
Bone Marrow Transplantation and Department of Clinical Chemistry, University Hospital Hamburg-Eppendorf, and A. K. St. Georg, Hamburg, Germany. nkroeger@uke.uni-hamburg.de
Krüger
W
W
Renges
H
H
Zabelina
T
T
Stute
N
N
Jung
R
R
Wittkowsky
G
G
Kuse
R
R
Zander
A
A
D000328:Adult; D006086:Graft vs Host Disease; D020350:Graft vs Tumor Effect; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery / Q000628:therapy*; D012074:Remission Induction; D014184:Transplantation, Homologous